{"url_path":"/sec/cvm/8-k/2026-05-14/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 ****Entry into a Material Definitive Agreement****.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/725363/0001654954-26-004910-index.html","accession_number":"0001654954-26-004910","cik":"0000725363","ticker":"CVM","issuer_name":"CEL SCI CORP","edgar_url":"https://www.sec.gov/Archives/edgar/data/725363/0001654954-26-004910-index.html","primary_entity_key":"0000725363","primary_entity_name":"CEL SCI CORP"},"word_count":76,"has_tables":true,"body_markdown":"**Item 1.01****Entry into a Material Definitive Agreement****.**\n\n \n\nOn May 11,2026 , the Company issued a press release, filed as Exhibit 99, concerning a strategic partnership, distribution, and revenue sharing agreement with Amarox for regulatory affairs, marketing and potential commercialization of Multikine (Leukocyte Interleukin, Injection) in the treatment of head and neck cancer in Saudi Arabia, with an optional extension for the Gulf Cooperation Council (GCC) countries including Bahrain, Kuwait, Oman, Qatar, and the United Arab Emirates."}